30 January 2023

Aptamer Group plc

("Aptamer", or " the Group")

Aptamer Group signs follow on project with multi-national consumer goods company

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, announces that following initial positive results from a project with a multi-national consumer goods company, it has signed a follow on deal to develop Optimer binders as novel solutions for a direct-to-consumer personal care product.

The deal could be worth up to £185,000, subject to the successful progression of Optimer development, and is the latest in a series of new contracts that demonstrates strong momentum in the first weeks of the second half of the year. Today's deal builds on announced work to date including £1.0m in signed orders and £1.0m of recognised H1 revenue announced in a recent trading update, as well as £500,000 from two fee-for-service contracts, announced last week.

Dr Arron Tolley, Chief Executive Officer, commented: "It's been a busy January at Aptamer, and this latest deal reflects the momentum within the business and the demand for our aptamer solutions.

"We're pleased to continue our work with this multi-national consumer goods company on this interesting personal care application, further validating our technology and our leadership position in developing novel aptamers. This deal also showcases the wider applicability of our technology and that Optimer binders can support improved solutions within the cosmetic development space. I look forward to reporting further progress on this highly exciting project."

- ENDS -

For further information, please contact:

Aptamer Group plc

Dr Arron Tolley                                                                               +44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser  

Andrew Emmott / Adam Dawes                                                          +44 (0) 20 3368 3550

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Cara Murphy                                         +44 (0) 20 3100 2000

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone                              +44 (0) 20 3709 5700

[email protected]

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer^® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.